Clinical trial
A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma
NCT00416273 · Janssen-Cilag G.m.b.H, Industry · Completed
Key facts
| NCT number | NCT00416273 |
|---|---|
| Title | A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma |
| Official title | Consolidation Therapy With Bortezomib <= 60 Year Old Patients With Multiple Myeloma |
| Lead sponsor | Janssen-Cilag G.m.b.H, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Bortezomib, No intervention |
| Enrollment | 217 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2013 |
| Completion | May 1, 2013 |
| First posted | Dec 27, 2006 |
| Last update posted | Mar 6, 2015 |
| Countries | Germany |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: